CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果